Octreotide acetate and Loperamide hydrochloride drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Octreotide acetate and Loperamide hydrochloride. Common interactions include weight decreased among females and abdominal pain among males.

The phase IV clinical study analyzes what interactions people who take Octreotide acetate and Loperamide hydrochloride have. It is created by eHealthMe based on reports of 10 people who take Octreotide acetate and Loperamide hydrochloride from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Dec, 07, 2022

10 people who take Octreotide acetate and Loperamide hydrochloride together, and have interactions are studied.

What is Octreotide acetate?

Octreotide acetate has active ingredients of octreotide acetate. eHealthMe is studying from 1,903 Octreotide acetate users for its effectiveness, alternative drugs and more.

What is Loperamide hydrochloride?

Loperamide hydrochloride has active ingredients of loperamide hydrochloride. It is often used in diarrhea. eHealthMe is studying from 7,602 Loperamide hydrochloride users for its effectiveness, alternative drugs and more.

Number of Octreotide acetate and Loperamide hydrochloride reports submitted per year:

Common Octreotide Acetate and Loperamide Hydrochloride drug interactions by gender *:

female:

Weight decreased
Cholelithiasis
Disease progression
Fatigue
Musculoskeletal chest pain
Myocardial infarction
Urosepsis
Abdominal distension
Abdominal pain
Arthralgia

male:

Abdominal pain
Anaemia
Gastrointestinal haemorrhage
Graft versus host disease
Interstitial lung disease
Malaise
Melaena
Metabolic acidosis
Renal failure
Respiratory failure

Common Octreotide Acetate and Loperamide Hydrochloride drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Blood pressure systolic increased
Electrocardiogram st-t change
Hypotension
Mitral valve incompetence
Myocardial ischaemia
Ventricular bigeminy
Ventricular hypokinesia
Ventricular tachycardia

30-39:

n/a

40-49:

n/a

50-59:

Abdominal pain
Blood lactate dehydrogenase increased
C-reactive protein increased
Dehydration
Drug ineffective
Faeces discoloured
Graft versus host disease
Interstitial lung disease
Malaise
Melaena

60+:

Fatigue
Cholelithiasis
Malignant neoplasm progression
Metastases to liver
Metastases to lymph nodes
Nausea
Oedema peripheral
Stomatitis
Vomiting
Weight decreased

Common conditions people have *:

Nausea (feeling of having an urge to vomit): 2 people, 20.00%
Infection: 2 people, 20.00%
Vitamin B12 Deficiency: 1 person, 10.00%
Insomnia (sleeplessness): 1 person, 10.00%
Cachexia (loss of weight): 1 person, 10.00%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 1 person, 10.00%
Depression: 1 person, 10.00%
Dizziness: 1 person, 10.00%
Hiv Infection: 1 person, 10.00%
Myoclonus (a brief, involuntary twitching of a muscle or a group of muscles): 1 person, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Octreotide acetate and Loperamide hydrochloride?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Saif MW, "Rheumatoid arthritis associated with the use of Sandostatin? LAR? depot in a patient with pancreatic neuroendocrine tumor", An association or a coincidence? The first case report, 2017 Jan .
Azkur D, Yoldas T, Toyran M, Kocabas CN, "A pediatric case of anaphylaxis due to octreotide", Asian Pacific journal of allergy and immunology, 2011 Dec .